KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zimmer Biomet Holdings (ZBH) EBITDA (2016 - 2025)

Zimmer Biomet Holdings (ZBH) has 17 years of EBITDA data on record, last reported at $154.5 million in Q4 2025.

  • For Q4 2025, EBITDA fell 60.28% year-over-year to $154.5 million; the TTM value through Dec 2025 reached $1.1 billion, down 14.59%, while the annual FY2025 figure was $1.1 billion, 14.59% down from the prior year.
  • EBITDA reached $154.5 million in Q4 2025 per ZBH's latest filing, down from $351.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $389.0 million in Q4 2024 and bottomed at -$28.3 million in Q4 2022.
  • Average EBITDA over 5 years is $267.1 million, with a median of $280.2 million recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 121.15% in 2022, then surged 1351.59% in 2023.
  • A 5-year view of EBITDA shows it stood at $133.8 million in 2021, then crashed by 121.15% to -$28.3 million in 2022, then soared by 1351.59% to $354.2 million in 2023, then grew by 9.82% to $389.0 million in 2024, then crashed by 60.28% to $154.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $154.5 million in Q4 2025, $351.3 million in Q3 2025, and $300.0 million in Q2 2025.